Drug Profile
Research programme: deubiquitinating enzyme inhibitors - Nynex therapeutics
Alternative Names: DUB inhibitors - Nynex Therapeurics; USP9X inhibitors - Nynex TherapeuticsLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator University of Michigan
- Developer Nynex Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Deubiquitinating enzyme inhibitors; USP9X protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Cancer in USA